Compare Gilead Sciences, Inc. (GILD) vs Grab Holdings Ltd. (GRAB) Price & Performance

Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.

Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.

GRAB trades at $3.19, up 3.57% today, with a bearish technical signal but strong fundamental momentum. The company has delivered three consecutive quarterly EPS beats, with Q2 2026 revenue up 22% year-over-year to $997 million. Recent news highlights a $1.49 billion acquisition of a majority stake in Atome Financial and a $30 million CEO share purchase, signaling confidence in growth. Cash flow trends show volatility, with 2025 net cash flow positive at $469 million but a projected decline to -$1.0 billion in 2026.

The outlook for GRAB is supported by robust revenue growth, expanding profitability, and aggressive financial services expansion, but risks include high capital expenditure, competitive pressures in Southeast Asia, and potential regulatory scrutiny. Analyst consensus is strongly bullish with 91.67% buy ratings, though technical indicators suggest near-term caution. The stock's valuation at a P/E of 28.27 reflects growth expectations but requires sustained execution to justify.